Publications by authors named "Krystal Capers"
Background: Patients newly initiated on opioids (OP), benzodiazepines (BZD), and antipsychotics (AP) during hospitalization are often prescribed these on discharge. Implications of this practice on outcomes remains unexplored.
Objective: To explore the prevalence and risk factors of new initiation of select OP, BZD and AP among patients requiring in-patient stays.
Objective: Injured tissue predisposes the subject to local and systemic infection. We studied injury-induced immune dysfunction seeking novel means to reverse such predisposition.
Background: Injury mobilizes primitive "DANGER signals" [danger-associated molecular patterns (DAMPs)] activating innate immunocyte (neutrophils, PMN) signaling and function.
Background: Adaptive support ventilation (ASV) is a partially closed-loop ventilation mode that adjusts tidal volume (V) and breathing frequency (f) to minimize mechanical work and driving pressure. ASV is routinely used but has not been widely studied in ARDS.
Methods: The study was a crossover study with randomization to intervention comparing a pressure-regulated, volume-targeted ventilation mode (adaptive pressure ventilation [APV], standard of care at Beth Israel Deaconess Medical Center) set to V 6 mL/kg in comparison with ASV mode where V adjustment is automated.
Background: Few therapies exist to treat severe COVID-19 respiratory failure once it develops. Given known diffuse pulmonary microthrombi on autopsy studies of COVID-19 patients, we hypothesized that tissue plasminogen activator (tPA) may improve pulmonary function in COVID-19 respiratory failure.
Methods: A multicenter, retrospective, observational study of patients with confirmed COVID-19 and severe respiratory failure who received systemic tPA (alteplase) was performed.
Article Synopsis
- The study investigates whether early treatment with tissue plasminogen activator (tPA) combined with heparin can improve lung function in patients suffering from severe respiratory failure due to COVID-19.
- Conducted between May 2020 and March 2021, the research involved two phases with a total of 50 participants who were randomized into treatment or control groups.
- Results indicated that patients receiving the tPA bolus showed significant improvements in their lung function, measured by the Pao to Fio ratio, without any severe bleeding incidents occurring in either treatment group.